Solasto (6197) Fundamentals 2026 — P/E 27.2x, Revenue Analysis | SniperIQ
Solasto (6197) is a JP-listed Healthcare company in Medical - Care Facilities with a market capitalization of ¥100.6B, trading at ¥1111.00 on the JPX. This SniperIQ fundamentals page covers Solasto's valuation (P/E 27.2x, P/B 4.1x), profitability (net margin 2.6%), revenue (¥141.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Solasto's market cap?
Solasto (6197) has a market capitalization of approximately ¥100.6B, trading at ¥1111.00 on the JPX. Market cap moves with the live share price.
What is Solasto's P/E ratio?
Solasto's trailing twelve-month P/E ratio is 27.2x, with a price-to-book (P/B) of 4.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Solasto?
Solasto runs a net profit margin of 2.6%, a gross margin of 15.3%, and an operating margin of 5.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Solasto generate?
Solasto reported revenue of ¥141.1B for fiscal year 2025, with net income of ¥3.7B and earnings per share (EPS) of 40.81. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Solasto pay a dividend?
Solasto offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Solasto financially healthy?
Solasto carries a debt-to-equity ratio of 0.77x and a current ratio of 1.34x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Solasto a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Solasto (6197) the key facts are: market cap ¥100.6B, P/E 27.2x, revenue ¥141.1B, 52-week range 417-1119. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Solasto's full fundamentals live
Get Solasto's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.